Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …
The endometrium is a highly dynamic and complex tissue lining the uterus, playing a central role in reproductive health. Despite its importance, the pathogenesis of many benign endometrial disorders remains …
Women with endometriosis and adenomyosis have an increased risk of age-dependent diseases such as cardiovascular disease and cancer. Whether this reflects differences in biological age is unknown.
Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, …
Adenomyosis and endometriosis are both recognized as etiological factors in the development of dysmenorrhea; however, their respective contributions to this condition remains ambiguous. This study aims to examine the distinct …
Adenomyosis can be categorized using various systems based on its extent, location, and severity. Depending on its location within the endometrium adenomyosis can be classified as intrinsic (inner myometrium) or …
Traditional Chinese medicine (TCM) functions according to the concepts of "holism" and treatment based on syndrome differentiation, and it has achieved good clinical results in treating patients with dysmenorrhea, which …
"Benign gynecologic conditions" is an umbrella term widely used to describe prevalent conditions such as endometriosis, adenomyosis, uterine fibroids, and genitourinary syndrome of menopause in clinical guidelines, research, reviews, and …
Pelvic MRI is increasingly performed as a second-line investigation in suspected complex cases of endometriosis, to precisely localize lesions and to optimise surgical planning. To facilitate MRI evaluation and inter-disciplinary …
The objective of this study is to evaluate the effectiveness of prolonged GnRH agonist (GnRH-a) suppression combined with letrozole and intensive luteal phase support in a patient with severe adenomyosis …